CN107660150B - Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 - Google Patents

Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 Download PDF

Info

Publication number
CN107660150B
CN107660150B CN201680013699.2A CN201680013699A CN107660150B CN 107660150 B CN107660150 B CN 107660150B CN 201680013699 A CN201680013699 A CN 201680013699A CN 107660150 B CN107660150 B CN 107660150B
Authority
CN
China
Prior art keywords
seq
antibody
free
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680013699.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107660150A (zh
Inventor
G·德尔瓦尔
E·席夫林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ab2 Bio SA
Original Assignee
Ab2 Bio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab2 Bio SA filed Critical Ab2 Bio SA
Publication of CN107660150A publication Critical patent/CN107660150A/zh
Application granted granted Critical
Publication of CN107660150B publication Critical patent/CN107660150B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
CN201680013699.2A 2015-03-05 2016-03-03 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 Active CN107660150B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15157742 2015-03-05
EP15157742.6 2015-03-05
EP15158781.3 2015-03-12
EP15158781 2015-03-12
EP15186626.6 2015-09-24
EP15186626 2015-09-24
PCT/EP2016/054524 WO2016139297A1 (en) 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Publications (2)

Publication Number Publication Date
CN107660150A CN107660150A (zh) 2018-02-02
CN107660150B true CN107660150B (zh) 2023-10-24

Family

ID=55453181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680013699.2A Active CN107660150B (zh) 2015-03-05 2016-03-03 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中

Country Status (17)

Country Link
US (4) US10882905B2 (enExample)
EP (1) EP3265807A1 (enExample)
JP (2) JP7274259B2 (enExample)
KR (1) KR102511343B1 (enExample)
CN (1) CN107660150B (enExample)
AU (1) AU2016227644B2 (enExample)
CA (1) CA2972689A1 (enExample)
CL (1) CL2017002237A1 (enExample)
CO (1) CO2017008940A2 (enExample)
IL (1) IL253292B2 (enExample)
MX (1) MX2017010919A (enExample)
MY (1) MY194040A (enExample)
PH (1) PH12017501402A1 (enExample)
RU (1) RU2755691C2 (enExample)
SG (1) SG11201706879UA (enExample)
UA (1) UA128752C2 (enExample)
WO (1) WO2016139297A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102321172B1 (ko) * 2013-09-05 2021-11-05 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
KR20200066623A (ko) 2017-09-06 2020-06-10 예일 유니버시티 인터류킨-18 변이체 및 사용 방법
CN112105640B (zh) * 2018-03-05 2025-03-04 詹森药业有限公司 检测神经退行性变的测定
WO2020018364A1 (en) * 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CN108929382B (zh) * 2018-07-20 2019-10-15 深圳市第三人民医院 一种抗serinc5的抗体及其应用
EP3892300A4 (en) 2018-12-03 2022-12-14 Mabprotein Co.,Ltd. ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION
MX2021008507A (es) 2019-01-18 2021-09-21 Univ Health Network Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112582058B (zh) * 2019-11-07 2022-04-01 广州医科大学 一种基于空气质量的慢阻肺发病预测方法及系统
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
AU2021283858A1 (en) * 2020-06-01 2023-01-05 Avalo Therapeutics, Inc. Methods and treatment involving antibodies to IL-18
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
TW202233237A (zh) 2020-11-18 2022-09-01 瑞士商諾華公司 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
MX2024007616A (es) * 2021-12-20 2024-09-04 Avalo Therapeutics Inc Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18.
CN117279950B (zh) * 2022-01-28 2025-08-08 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas
MX2024011278A (es) * 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
CN120693345A (zh) 2023-01-06 2025-09-23 艾利妥 抗il18结合蛋白抗体及其使用方法
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
CN119192356B (zh) * 2024-09-29 2025-05-27 华中农业大学 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用
CN119241693B (zh) * 2024-09-29 2025-05-27 华中农业大学 一种抗犬瘟热病毒的基因工程嵌合抗体及应用
CN120349409A (zh) * 2025-04-08 2025-07-22 生物岛实验室 Il-18bp纳米抗体及其制备方法与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352650A (zh) * 1999-03-19 2002-06-05 史密丝克莱恩比彻姆公司 用于治疗il－18介导疾病的重组il－18拮抗物
WO2002032374A3 (en) * 2000-10-18 2002-09-19 Immunex Corp Methods for treating il-18 mediated disorders
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN1499982A (zh) * 2001-01-29 2004-05-26 Ӧ���о�ϵͳARS�ɷݹ�˾ Il-18抑制剂在治疗和/或预防心脏病中的应用
CN1535160A (zh) * 2001-05-25 2004-10-06 ����˹ó�׹ɷ����޹�˾ Il-18抑制剂在治疗或预防中枢神经系统损伤中的应用
CN1902229A (zh) * 2003-11-12 2007-01-24 艾博特公司 Il－18结合蛋白
CN101062415A (zh) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN103339147A (zh) * 2010-12-20 2013-10-02 米迪缪尼有限公司 抗il-18抗体和其用途
CN105722858A (zh) * 2013-09-05 2016-06-29 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
AU1235692A (en) 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
ES2176342T5 (es) 1994-10-21 2010-02-09 Innogenetics N.V. Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
JP2004500086A (ja) 2000-02-10 2004-01-08 アボット・ラボラトリーズ ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法
SK287761B6 (en) 2000-05-05 2011-09-05 Applied Research Systems Ars Holding N. V. Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
JP4502580B2 (ja) 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
MXPA04009135A (es) * 2002-03-22 2004-12-07 Applied Research Systems Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas.
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2309508T3 (es) 2003-03-11 2008-12-16 Laboratoires Serono Sa Vectores de expresion que comprenden el promotor de mcmv-ie2.
ATE549353T1 (de) 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2011224023C1 (en) 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
CN101039696B (zh) 2004-08-20 2011-08-17 史密丝克莱恩比彻姆公司 给药人il-18治疗创伤的方法
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE503846T1 (de) 2005-09-15 2011-04-15 Val Chum S E C Verfahren zur diagnose eines ovarialkarzinoms
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2017010919A (es) * 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352650A (zh) * 1999-03-19 2002-06-05 史密丝克莱恩比彻姆公司 用于治疗il－18介导疾病的重组il－18拮抗物
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN101062415A (zh) * 2000-02-21 2007-10-31 应用研究系统Ars股份公司 Il－18抑制剂的应用
WO2002032374A3 (en) * 2000-10-18 2002-09-19 Immunex Corp Methods for treating il-18 mediated disorders
CN1499982A (zh) * 2001-01-29 2004-05-26 Ӧ���о�ϵͳARS�ɷݹ�˾ Il-18抑制剂在治疗和/或预防心脏病中的应用
CN1535160A (zh) * 2001-05-25 2004-10-06 ����˹ó�׹ɷ����޹�˾ Il-18抑制剂在治疗或预防中枢神经系统损伤中的应用
CN1902229A (zh) * 2003-11-12 2007-01-24 艾博特公司 Il－18结合蛋白
CN103339147A (zh) * 2010-12-20 2013-10-02 米迪缪尼有限公司 抗il-18抗体和其用途
CN105722858A (zh) * 2013-09-05 2016-06-29 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Diagnosis and management of adult onset Still’s;P Efthimiou;《Ann Rheum Dis》;20051011;第65卷;第564-572页 *
High circulating levels of free interleukin-18 in patients with active SLE;Daniela Novick;《Journal of Autoimmunity》;20101231;第34卷;第121-126页 *
Role of IL-18 in acute lung inflammation;J A Jordan;《J Immunol》;20011215;第167卷(第12期);第7060-7068页 *
Role of IL-18 in Acute Lung Inflammation;Jacqueline A. Jordan;《J Immunol》;20011231;第167卷;第7060-7068页 *

Also Published As

Publication number Publication date
JP2018513116A (ja) 2018-05-24
US20210188968A1 (en) 2021-06-24
IL253292B2 (en) 2023-05-01
US20240190952A1 (en) 2024-06-13
US11926663B2 (en) 2024-03-12
JP2021176860A (ja) 2021-11-11
CL2017002237A1 (es) 2018-03-09
IL253292A (en) 2017-09-28
PH12017501402A1 (en) 2018-01-15
NZ733897A (en) 2023-11-24
SG11201706879UA (en) 2017-09-28
US10882905B2 (en) 2021-01-05
KR102511343B1 (ko) 2023-03-17
WO2016139297A1 (en) 2016-09-09
IL253292B1 (en) 2023-01-01
CA2972689A1 (en) 2016-09-09
RU2755691C2 (ru) 2021-09-20
AU2016227644B2 (en) 2022-06-16
CN107660150A (zh) 2018-02-02
CO2017008940A2 (es) 2017-11-10
US20200377586A1 (en) 2020-12-03
RU2017134857A (ru) 2019-04-09
EP3265807A1 (en) 2018-01-10
RU2017134857A3 (enExample) 2019-12-23
JP7274259B2 (ja) 2023-05-16
US20180127494A1 (en) 2018-05-10
MX2017010919A (es) 2017-12-07
BR112017017076A2 (pt) 2018-04-10
AU2016227644A1 (en) 2017-07-20
UA128752C2 (uk) 2024-10-16
MY194040A (en) 2022-11-09
US11820817B2 (en) 2023-11-21
KR20170121199A (ko) 2017-11-01

Similar Documents

Publication Publication Date Title
CN107660150B (zh) Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US20230250164A1 (en) IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases
RU2810206C1 (ru) Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях
CA2922498C (en) Il-18 binding protein (il-18bp) in inflammatory diseases
BR112017017076B1 (pt) Uso de il-18bp
JP2025507007A (ja) Ｖｅｘａｓの治療におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）
HK1221726B (en) Il-18 binding protein (il-18bp) in inflammatory diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment